Regenxbio Inc (RGNX) said after close Tuesday that it lost $1.38 per share in quarter four 2022.
On the revenue line, the company reported $31.3 million, missing estimates by $6.1 million.
In the same quarter a year ago, the company earned $6.67 per share on revenue of $398.7 million.
The stock is up 10.29% to $24.60 after the report.
Regenxbio Inc's profit margins took a hit as earnings fell at a faster pace than revenues.
Wall Street Analysts had an average rating of Buy on the stock prior to the report.
InvestorsObserver gives the stock a Bullish Sentiment score at the moment based on recent trading.
Prior to the report, InvestorsObserver gave the stock an overall score of 63. Meanwhile, the average Wall Street analyst rated the stock a Buy.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno-associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa).
News Home
Regenxbio Inc Up 10.29% To $24.60 After Earnings Miss
Mentioned in this article
